C-MER Eye Care Holdings Full Year 2023 Earnings: EPS: HK$0.049 (vs HK$0.018 loss in FY 2022)

C-MER Eye Care Holdings (HKG:3309) Full Year 2023 Results

Key Financial Results

• Revenue: HK$1.92b (up 11% from FY 2022).
• Net income: HK$62.0m (up from HK$21.9m loss in FY 2022).
• Profit margin: 3.2% (up from net loss in FY 2022). The move to profitability was driven by higher revenue.
• EPS: HK$0.049 (up from HK$0.018 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the HK Medical Business segment contributing a total revenue of HK$932.1m (48% of total revenue). Notably, cost of sales worth HK$1.31b amounted to 68% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to HK$355.1m (64% of total expenses). Explore how 3309's revenue and expenses shape its earnings.

C-MER Eye Care Holdings' share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for C-MER Eye Care Holdings that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.